Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR Inhibitor for relapsed chronic lymphocytic leukemia

We report on a patient with relapsed chronic lymphocytic leukemia (CLL) treated with the novel mTOR inhibitor RAD001 within a phase II clinical trial. Although the patient initially responded to therapy, RAD001 was discontinued after 32 weeks due to progression and fludarabine-based chemotherapy was started. The patient subsequently developed a rapidly fatal Epstein-Barr-virus-associated lymphoproliferative disorder, clonally unrelated to the CLL. The clinical course suggests caution when using newer immunosuppressive drugs for treatment of CLL, especially in the context of additional purine analog therapy.

[1]  E. Morra,et al.  Significance of Epstein-Barr virus (EBV) load and Interleukin-10 in post-transplant lymphoproliferative disorders , 2005, Leukemia & lymphoma.

[2]  C. Peschel,et al.  Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: A new therapeutic option , 2005, Leukemia & lymphoma.

[3]  A. Friedman,et al.  The evolving experience using everolimus in clinical transplantation. , 2004, Transplantation proceedings.

[4]  H. Kantarjian,et al.  Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia , 2003, Cancer.

[5]  Y. Natkunam,et al.  Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. , 2003, Cancer research.

[6]  J. Dancey.  Clinical development of mammalian target of rapamycin inhibitors. , 2002, Hematology/oncology clinics of North America.

[7]  J. Manning,et al.  Epstein–Barr Virus-Positive B-Cell Lymphoproliferative Disorders Arising in Immunodeficient Patients Previously Treated With Fludarabine for Low-Grade B-Cell Neoplasms , 2002, The American journal of surgical pathology.

[8]  P. Nowell,et al.  The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[9]  E. Jaffe,et al.  Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. , 1999, Blood.

[10]  C. Peschel,et al.  Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. , 2003, Blood.